Lbl-007

3 trials

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

2 Sponsors

5 Countries

Phase II

Phase I (FiH)

Phase II: 2 Phase I (FiH): 1

Indications tested

Squamous cell carcinoma of head and neck 2 Non-small cell lung cancer 1 Renal cell carcinoma 1

Sponsors using this IMP

BeOne Medicines AG 2 Beigene Ltd. 1

All trials

3 total

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer. Ended

2022-502738-18-00 Phase II 4 countries BeOne Medicines AG
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended

2023-503418-63-00 Phase II 3 countries BeOne Medicines AG
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended

2022-500694-14-00 Phase I (FiH) 4 countries Beigene Ltd.

Showing 1–3 of 3 trials

← All drugs A–Z